“We are hearing about other antibody-drug conjugates, other agents in metastatic disease with a positive hormone receptor and the next generation of drugs that we will use to treat our patients.”
With an abundance of data presented at the San Antonio Breast Cancer Symposium in 2020, there is much to expect in the advancement of breast cancer, according to Kevin Kalinsky, MD, MS.
Kalinsky, acting associate professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine, as well as director of the Glenn Family Breast Center and medical breast oncology at Emory University’s Winship Cancer Institute, spoke with CancerNetwork® about the exciting drugs that are falling at the peak in the treatment of breast cancer.
I think we are seeing growing data on the role of CDK4 / 6 inhibitors in the operable environment and also in the metastatic environment … The other thing I am interested in is just the new therapies that are falling off the peak. We will obtain some additional information on some approved drugs, such as trastuzumab [Herceptin], for example, in breast cancer patients. I think we are also hearing about other antibody-drug conjugates, other agents in metastatic disease with a positive hormone receptor and the next generation of drugs that we will use to treat our patients. There’s a lot going down.